Pat McAleer raises his fist in celebration after reaching the Atlantic Ocean at Virginia Beach, VA. On July 15, Pat McAleer flew from Richmond, VA, to Seattle, WA, dipped his bike in the Pacific Ocean ...
On March 6, 2027, the Breakthrough T1D community will gather at San Francisco City Hall for the 28th Annual San Francisco Gala. This year’s Impact Award goes to Betsy and Dan Wright, in recognition of ...
Disease-modifying therapies (DMTs) are treatments that prevent, slow, or reverse type 1 diabetes (T1D) by preserving or restoring insulin-producing beta cells. While there are several DMTs in clinical ...
“Unannounced Meals” Functionality Would Provide Significant Quality-of-Life Improvements for People Living with Type 1 Diabetes PALO ALTO, Calif., Oct. 22, 2026—Tidepool, a non-profit leader advancing ...
A new clinical trial is investigating tegoprubart with islet cell transplants in people with type 1 diabetes and kidney disease.
A new clinical trial funded by Breakthrough T1D recently launched and is testing islet cell transplantation paired with Eledon Pharmaceuticals’ investigational immunosuppression therapy tegoprubart in ...
PHILADELPHIA, Pa., Oct. 12, 2026 – Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough ...
Today, the U.S. Food and Drug Administration (FDA) approved finerenone (brand name Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated ...
Sana’s novel cell therapy approach is designed to help transplanted islet cells evade immune attack while continuing to produce insulin. The strategy uses gene editing to create hypoimmune islet cells ...
Living with type 1 diabetes (T1D) means managing the disease every day while navigating its complexities. That’s why dispelling common myths and misconceptions is so important. They can make life even ...
In an exciting update for the type 1 diabetes (T1D) community, Tzield—the first disease-modifying therapy approved by the FDA to delay progression of stage 2 T1D—has now been approved by the FDA for ...
New data presented this week at the American Diabetes Association’s (ADA) 86th Scientific Sessions in New Orleans shows incredible promise: all 12 participants in an islet cell transplant trial are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results